Gilliland Jeter Wealth Management LLC Acquires 319 Shares of Eli Lilly and Company $LLY

Key Points

• Gilliland Jeter Wealth Management LLC increased its stake in Eli Lilly and Company by 26.1%, acquiring an additional 319 shares, bringing its total holdings to 1,543 shares valued at approximately $1.2 million.
• Insider purchases at Eli Lilly include CEO David A. Ricks buying 1,632 shares for over $1 million, indicating strong confidence from leadership in the company's future.
• Wall Street analysts have a mixed outlook on Eli Lilly, with ratings ranging from Strong Buy to Hold, and an average target price of $948.56, showing potential for growth despite recent downgrades.

Gilliland Jeter Wealth Management LLC raised its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 26.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,543 shares of the company's stock after buying an additional 319 shares during the period. Gilliland Jeter Wealth Management LLC's holdings in Eli Lilly and Company were worth $1,203,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in the business. Hobbs Wealth Management LLC grew its position in Eli Lilly and Company by 0.8% during the 1st quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock valued at $1,205,000 after purchasing an additional 12 shares during the last quarter. Hixon Zuercher LLC grew its position in Eli Lilly and Company by 0.7% during the 1st quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock valued at $1,477,000 after purchasing an additional 12 shares during the last quarter. O Brien Wealth Partners LLC grew its position in Eli Lilly and Company by 25.5% during the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after purchasing an additional 12 shares during the last quarter. Ascent Capital Management LLC grew its position in Eli Lilly and Company by 2.5% during the 1st quarter. Ascent Capital Management LLC now owns 495 shares of the company's stock valued at $409,000 after purchasing an additional 12 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners grew its position in Eli Lilly and Company by 2.7% during the 1st quarter. Tennessee Valley Asset Management Partners now owns 493 shares of the company's stock valued at $407,000 after purchasing an additional 13 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Insider Activity at Eli Lilly and Company

In other news, CEO David A. Ricks bought 1,632 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were bought at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the purchase, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director J Erik Fyrwald bought 1,565 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the purchase, the director owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 4,514 shares of company stock worth $2,894,841 in the last 90 days. Insiders own 0.13% of the company's stock.

Wall Street Analysts Forecast Growth

LLY has been the topic of several recent analyst reports. Wall Street Zen downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research report on Saturday, September 20th. Cantor Fitzgerald set a $925.00 price target on shares of Eli Lilly and Company and gave the company an "overweight" rating in a report on Thursday. Berenberg Bank reaffirmed a "hold" rating and set a $830.00 price target (down previously from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Eli Lilly and Company in a report on Wednesday. Finally, JPMorgan Chase & Co. dropped their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a report on Tuesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $948.56.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $854.40 on Friday. The firm's 50 day moving average price is $740.99 and its 200-day moving average price is $766.49. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $937.00. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The stock has a market capitalization of $808.66 billion, a PE ratio of 55.84, a price-to-earnings-growth ratio of 1.18 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter in the prior year, the business earned $3.92 EPS. The business's quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.